Sign Up
OverviewAPI
The global sickle cell disease treatment market is projected to reach USD 12.38 billion by 2032, with North America leading the way. The UK has approved a gene-editing medication for sickle-cell disease. Market dynamics include growing knowledge of the disease, adverse effects of treatments, and challenges in access to treatment.

Ask a question